EE9600197A - Uudsed 1,1-bis(heteroasolüül)alkaani derivaadid ja nende kasutamine neuroprotektiivsete ainetena - Google Patents
Uudsed 1,1-bis(heteroasolüül)alkaani derivaadid ja nende kasutamine neuroprotektiivsete ainetenaInfo
- Publication number
- EE9600197A EE9600197A EE9600197A EE9600197A EE9600197A EE 9600197 A EE9600197 A EE 9600197A EE 9600197 A EE9600197 A EE 9600197A EE 9600197 A EE9600197 A EE 9600197A EE 9600197 A EE9600197 A EE 9600197A
- Authority
- EE
- Estonia
- Prior art keywords
- heteroazolyl
- bis
- novel
- neuroprotective agents
- alkane derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9401965A SE9401965D0 (sv) | 1994-06-07 | 1994-06-07 | New compounds |
| PCT/SE1995/000604 WO1995033747A1 (en) | 1994-06-07 | 1995-05-29 | Novel 1,1-bis(heteroazolyl)alkane derivatives and their use as neuroprotective agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EE9600197A true EE9600197A (et) | 1997-06-16 |
Family
ID=20394274
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EE9600197A EE9600197A (et) | 1994-06-07 | 1995-05-29 | Uudsed 1,1-bis(heteroasolüül)alkaani derivaadid ja nende kasutamine neuroprotektiivsete ainetena |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US5843971A (et) |
| EP (1) | EP0765325A1 (et) |
| JP (1) | JPH10503172A (et) |
| CN (1) | CN1051546C (et) |
| AU (1) | AU691303B2 (et) |
| BR (1) | BR9507923A (et) |
| CA (1) | CA2190128A1 (et) |
| CZ (1) | CZ357796A3 (et) |
| DZ (1) | DZ1895A1 (et) |
| EE (1) | EE9600197A (et) |
| FI (1) | FI964879A (et) |
| HR (1) | HRP950302A2 (et) |
| HU (1) | HUT76050A (et) |
| IL (1) | IL113773A (et) |
| IS (1) | IS4383A (et) |
| MA (1) | MA23574A1 (et) |
| NO (1) | NO307421B1 (et) |
| NZ (1) | NZ287973A (et) |
| PL (1) | PL318470A1 (et) |
| RU (1) | RU2155763C2 (et) |
| SE (1) | SE9401965D0 (et) |
| SK (1) | SK155696A3 (et) |
| TN (1) | TNSN95065A1 (et) |
| WO (1) | WO1995033747A1 (et) |
| YU (1) | YU38695A (et) |
| ZA (1) | ZA954145B (et) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9401965D0 (sv) * | 1994-06-07 | 1994-06-07 | Astra Ab | New compounds |
| US6921538B2 (en) * | 2002-05-10 | 2005-07-26 | Allergan, Inc. | Therapeutic treatments for neuropsychiatric disorders |
| US7649098B2 (en) * | 2006-02-24 | 2010-01-19 | Lexicon Pharmaceuticals, Inc. | Imidazole-based compounds, compositions comprising them and methods of their use |
| TW200920355A (en) * | 2007-09-06 | 2009-05-16 | Lexicon Pharmaceuticals Inc | Compositions and methods for treating immunological and inflammatory diseases and disorders |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2801794A1 (de) * | 1978-01-17 | 1979-07-19 | Basf Ag | Verfahren zur herstellung von thiazolderivaten und neue thiazole |
| US5554620A (en) * | 1993-09-14 | 1996-09-10 | Sterling Winthrop Inc. | Substituted 6,11-ethano-6,11-dihydrobenzo[b] quinolizinium salts and compositions and methods of use thereof |
| SE9401965D0 (sv) * | 1994-06-07 | 1994-06-07 | Astra Ab | New compounds |
-
1994
- 1994-06-07 SE SE9401965A patent/SE9401965D0/xx unknown
-
1995
- 1995-05-18 IL IL11377395A patent/IL113773A/xx not_active IP Right Cessation
- 1995-05-22 HR HR9401965-0A patent/HRP950302A2/xx not_active Application Discontinuation
- 1995-05-22 ZA ZA954145A patent/ZA954145B/xx unknown
- 1995-05-29 RU RU97100178/04A patent/RU2155763C2/ru active
- 1995-05-29 CZ CZ963577A patent/CZ357796A3/cs unknown
- 1995-05-29 BR BR9507923A patent/BR9507923A/pt not_active Application Discontinuation
- 1995-05-29 JP JP8500744A patent/JPH10503172A/ja active Pending
- 1995-05-29 WO PCT/SE1995/000604 patent/WO1995033747A1/en not_active Application Discontinuation
- 1995-05-29 EP EP95922031A patent/EP0765325A1/en not_active Ceased
- 1995-05-29 SK SK1556-96A patent/SK155696A3/sk unknown
- 1995-05-29 CN CN95193504A patent/CN1051546C/zh not_active Expired - Fee Related
- 1995-05-29 PL PL95318470A patent/PL318470A1/xx unknown
- 1995-05-29 CA CA002190128A patent/CA2190128A1/en not_active Abandoned
- 1995-05-29 EE EE9600197A patent/EE9600197A/et unknown
- 1995-05-29 NZ NZ287973A patent/NZ287973A/en unknown
- 1995-05-29 US US08/448,411 patent/US5843971A/en not_active Expired - Fee Related
- 1995-05-29 AU AU26859/95A patent/AU691303B2/en not_active Ceased
- 1995-05-29 HU HU9603386A patent/HUT76050A/hu unknown
- 1995-06-01 MA MA23913A patent/MA23574A1/fr unknown
- 1995-06-06 TN TNTNSN95065A patent/TNSN95065A1/fr unknown
- 1995-06-07 US US08/485,719 patent/US5665747A/en not_active Expired - Fee Related
- 1995-06-07 YU YU38695A patent/YU38695A/sh unknown
- 1995-07-03 DZ DZ950069A patent/DZ1895A1/fr active
-
1996
- 1996-11-12 IS IS4383A patent/IS4383A/is unknown
- 1996-12-04 NO NO965182A patent/NO307421B1/no not_active IP Right Cessation
- 1996-12-05 FI FI964879A patent/FI964879A/fi unknown
Also Published As
| Publication number | Publication date |
|---|---|
| YU38695A (sh) | 1998-12-23 |
| HUT76050A (en) | 1997-06-30 |
| CN1150426A (zh) | 1997-05-21 |
| MA23574A1 (fr) | 1995-12-31 |
| DZ1895A1 (fr) | 2002-02-17 |
| US5665747A (en) | 1997-09-09 |
| EP0765325A1 (en) | 1997-04-02 |
| SK155696A3 (en) | 1997-05-07 |
| IL113773A0 (en) | 1995-08-31 |
| US5843971A (en) | 1998-12-01 |
| CN1051546C (zh) | 2000-04-19 |
| IS4383A (is) | 1996-11-12 |
| RU2155763C2 (ru) | 2000-09-10 |
| NO307421B1 (no) | 2000-04-03 |
| ZA954145B (en) | 1995-12-07 |
| AU691303B2 (en) | 1998-05-14 |
| AU2685995A (en) | 1996-01-04 |
| TNSN95065A1 (fr) | 1996-02-06 |
| NZ287973A (en) | 1998-04-27 |
| CA2190128A1 (en) | 1995-12-14 |
| NO965182D0 (no) | 1996-12-04 |
| FI964879A0 (fi) | 1996-12-05 |
| HU9603386D0 (en) | 1997-01-28 |
| IL113773A (en) | 2000-02-29 |
| BR9507923A (pt) | 1997-09-23 |
| FI964879A (fi) | 1996-12-05 |
| NO965182L (no) | 1996-12-04 |
| PL318470A1 (en) | 1997-06-23 |
| SE9401965D0 (sv) | 1994-06-07 |
| JPH10503172A (ja) | 1998-03-24 |
| WO1995033747A1 (en) | 1995-12-14 |
| CZ357796A3 (en) | 1997-06-11 |
| HRP950302A2 (en) | 1997-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69526966T2 (de) | Hautkräftigende kometische zusammensetzung | |
| CY2013003I2 (el) | Φωσφονοκεφεμικα παραγωγα, διαδικασια για την παρασκευη τους, και χρηση αυτων | |
| BR9508318A (pt) | Composição impadora concentrada | |
| DE69842237D1 (de) | Azeotropische Zusammensetzungen enthaltend 1,1,1,2,3,3,3-Heptafluorpropan und Verfahren, die diese Zusammensetzungen verwenden | |
| FI954773A (fi) | Antihypertriglyserideeminen koostumus | |
| FI960076A (fi) | Uudet (1-heteroatsolyyli-1-heterosyklyyli) alkaanijohdannaiset ja niiden käyttö hermostoa suojaavina aineina | |
| FI964031A0 (fi) | Bentsamidijohdannainen, mainittua johdannaista sisältävät koostumukset ja sen käyttö | |
| FI972306A0 (fi) | Substituoituja 2-aryylikarbonyylioksimetyyli-1,2,5-tiadiatsolidin -3- oni-1,1-dioksidi-johdannaisia ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi | |
| DE58902899D1 (de) | 2',3'-dideoxypurinnucleosid/purinnucleosid-phosphorylase-inhibitor kombinationstherapie und zusammensetzungen dafuer. | |
| NO20001288D0 (no) | Substituerte 1,2,3,4,5,6-heksahydro-2,6-metano-3-benzazocin- 10-oler, fremgangsmÕte for fremstilling derav og anvendelse som legemiddel | |
| ITMI940362A0 (it) | Composizione antitosse | |
| HU9503742D0 (en) | Novel (1-phenyl-1-heterocyclyl) alkane derivatives and their use as neuroprotective agents | |
| EE9600197A (et) | Uudsed 1,1-bis(heteroasolüül)alkaani derivaadid ja nende kasutamine neuroprotektiivsete ainetena | |
| FR2695297B1 (fr) | Composition d'agent désinfectant. | |
| BR9508248A (pt) | 1,2,4,6-Tiatriazinas herbicidas | |
| FI972674A0 (fi) | 3,3-(disubstituoituja)sykloheksan-1-olimonomeerejä ja vastaavia yhdisteitä | |
| DE69519440D1 (de) | Verbesserte, änderbare zusammensetzung | |
| DE69525472T2 (de) | Markierungszusammensetzung | |
| FI950101A (fi) | 4-oksa-1-atsabisyklo 3,2,0 -7heptanoni-johdannaiset kasvainten vastaisina aineina | |
| ITMI941593A1 (it) | Tetraidropiridine 3, 3-disostituite | |
| KR940025922U (ko) | 깃 착탈식 와이셔츠 | |
| SE9404519D0 (sv) | New composition | |
| NO924046L (no) | 2[, 3[-dideoksy-4[-tioribonukleosider som antivirusmidler | |
| ITEN940002U1 (it) | G.s.50 | |
| ATE82855T1 (de) | 2',3'-dideoxypurinnucleosid/purinnucleosidphosphorylase-inhibitor kombinationstherapie und zusammensetzungen dafuer. |